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A B S T R A C T
Rubinstein-Taybi syndrome (RSTS) is a neurodevelopmental disorder characterized by growth retardation, skeletal anomalies and intellectual disability, caused
by heterozygous mutations in either CREBBP (RSTS1) or EP300 (RSTS2) genes. We characterized 3 iPSC lines generated by Sendai from blood of RSTS1 patients
with unique non sense c.4435G > T, p.(Gly1479*), c.3474G > A, p.(Trp1158*) and missense c.4627G > T, p.(Asp1543Tyr) CREBBP mutations. All lines
displayed iPSC morphology, pluripotency markers, trilineage differentiation potential, stable karyotype and specific mutations. Western-blot using a CREB-
Binding Protein N-terminus antibody demonstrated the same amount of full length protein as control in the missense mutation line and reduced amount in lines
with stop mutations.
Resource details
Rubinstein-Taybi syndrome (RSTS) is a rare multiple congenital
anomaly and intellectual disability syndrome characterized by growth
retardation, skeletal deformities and cognitive impairment, mainly
caused by de novo heterozygous mutation in either CREBBP or EP300
genes, encoding the homologous acetyltransferases and transcrip-
tional coactivators CBP and p300. RSTS1 results from inactivating or
missense CREBBP mutations leading to CBP protein either in reduced
quantity or defective in enzymatic function. RSTS1 accounts for 60%
of clinically diagnosed RSTS patients, versus 10% accounted for by
RSTS2, hence representing the main RSTS entity. The overall clinical
phenotype, and particularly cognitive impairment is more severe than
that of RSTS2 (Hennekam, 2006). Following institutional ethical
committee approval and patient informed consent, peripheral blood
was withdrawn from three patients carrying CREBBP mutations
(Table 1) who have been clinically and molecularly described under
the codes 34, 149 (inactivating mutations) and 46 (missense muta-
tion) (Bentivegna et al., 2006; Lopez-Atalaya et al., 2012; Spena et al.,
2015). The original patients' codes are included in the alternative
names of the iPSC lines (Table 1). Induced pluripotent stem cells
(iPSCs) were generated from peripheral blood mononuclear cells
(PBMNCs) using integration-free Sendai virus (SeV) particles trans-
ducing target cells with replication-competent RNAs encoding the four
reprogramming Yamanaka factors. iPSCs were grown on irradiated
Mouse Embryonic Fibroblasts (MEF) feeder layers. Twenty days after
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reprogramming, iPSC colonies were manually selected and culture
expanded. The iPSC lines described here, named IAIi002RSTS1-34-A,
IAIi003RSTS1-46-A and IAIi004RSTS1-149-A were characterized by
evaluating distinctive morphology and expression of the pluripotency
markers by immunofluorescence and FACS (SSEA4, OCT3/4, TRA-1-
60, Fig. 1A; 99% SSEA4+ cells; 81%,91% and 94% TRA-1-60+ cells,
Fig. 1B); potential to differentiate along ectodermal, TRA1-60+ cells,
mesodermal and endodermal lineages (NESTIN/PAX6, αSMA and
SOX17, Fig. 1C). Cytogenetic analysis, performed on> 30 mitoses,
showed that all three iPSC lines were karyotypically normal in the
number and structure of chromosomes at passage 6 (P6) (Suppl
Fig. 1). Array-Comparative Gnome Hybridization (a-CGH) also ruled
out submicroscopic rearrangements and allowed by CNVs analysis to
match the identity of the three iPSC lines to that of donor patients
peripheral blood cells (Table 2). Sanger sequencing on extracted DNAs
revealed the patients germline CREBBP exon 27 non sense mutation
c.4435G > T (p.(Gly1479*)), exon 28 missense mutation
c.4627G > T (p.(Asp1543Tyr)) and exon 18 non sense mutation
c.3474G > A (p.(Trp1158*)) (Fig. 1D). Western Blot analysis using
an antibody recognizing CREB Binding Protein (CBP) N-terminus
showed that full length CBP was present in the same amount than in
control cells in IAIi003RSTS1-46-A (carrying a missense mutation),
while it was reduced in IAIi002RSTS1-34-A and IAIi4004RSTS1-149-A
lines (carrying non sense mutations) (Fig. 1E) by 46% and 68%, re-
spectively, as shown by densitometry (CBP: actin ratio) (Fig. 1F).
Materials and methods
Reprogramming of RSTS2 patients' erythroblasts to iPSCs
PBMCs were collected via gradient centrifugation from blood of 3
RSTS1 patients with CREBBP mutations (Table 1) and cultured for
9 days in enriched StemSpan™ Medium (Stemcell Technologies) at
37 °C in 5% CO2. Reprogramming was performed by SeV (Cytotune
2.0, LifeTech) (Soares et al., 2016). Transduced cells were plated on
MEF feeders in HESC (human embryonic stem cell) medium (DMEM-
F1220% KOSR, 1 mM L-glutamine, 1×NEAA, 4 ng/ml FGF (all re-
agents from Life Technologies) and 100mM β-mercaptoethanol
(Sigma)) and fed every other day. Colonies were picked at day 20 and
manually passaged weekly by cutting through the single colony in
several places with a sterile syringe needle and then removing the
colony by scraping it. Passage ratio was 1:5. iPSCs were harvested in
60% HESC medium, 30% FBS and 10% DMSO and stored in liquid
nitrogen.
Pluripotency marker immunocytochemistry
Cells were fixed in 4% paraformaldehyde (20min, 37 °C).
Antibodies in gelatin dilution buffer (0.2% gelatin (for blocking),
0.3% Triton-X 100 (for permeabilization), 20mM Sodium Phosphate
Buffer pH 7.4, 0.45M NaCl, all by Sigma) were incubated at 4 °C
overnight (primary) and 2 h at RT (secondary). Images were acquired
with a Nikon Eclipse Ti microscope. Nuclei were counterstained with
DAPI.
Flow cytometry
iPSCs were dissociated in PBS/0.5 mM EDTA, fixed using BD
Cytofix™ buffer (BD Biosciences) and stained with TRA-1-60 or SSEA4
antibody (both 1 h, 4 °C) followed by the specific fluorescently tagged
secondary antibody (1 h 4 °C). Cells were analyzed using a Gallios
(Beckman Coulter) flow cytometer and Kaluza software. An iPSC line
from a healthy donor was used as a characterization control.
In vitro trilineage differentiation potential assay
iPSCs were cultured on vitronectin-coated chamber slides and dif-
ferentiated using the STEMdiff™ trilineage differentiation kit (Stemcell
Technologies) according to the manufacturer's instructions. (primary
and secondary antibody details in Table 3.)
Karyotyping
Chromosomes were prepared from the 3 iPSCs at P6. After colcemid
(10 μg/ml) overnight at 37 °C (5% CO2, 95% rH) iPSCs were incubated
in hypotonic solution (KCl 0.56%) at RT for 6min, washed with acetic
acid 5% for 3min, fixed with methanol/acetic acid (3:1). Q-banded
metaphases were photographed at 100× (Leica microscope and
camera) and karyotyped (> 30 mitoses) using CytoVision software
(Leica).
Array-CGH analysis
High-resolution a-CGH was performed on genomic blood and iPSC
DNA using the SurePrint G3 Human CGH Microarray Kit 4x180K in
accordance with the manufacturer's instructions (Agilent
Technologies). Data were then extracted and analyzed for copy number
changes using Agilent CytoGenomics v.3.0.
CREBBP mutation analysis by Sanger sequencing
Genomic DNA was extracted from iPSCs using QIAmp DNA Mini kit
(Qiagen). CREBBP exons 27, 28, 18 were amplified with GoTaq Flexi
DNA polymerase (Promega) using exon flanking primers (details in
Table 4) and sequenced with Big Dye Terminator v.1.1 Cycle Sequen-
cing kit (Applied Biosystems). Electropherograms were analyzed with
ChromasPro software 2.1.5 (Technelysium Pty Ltd) using
ENSG00000005339 as the CREBBP reference.
Western Blot
Cells grown on vitronectin were pelleted and lysed in ice-cold
50mM Tris-HCl (pH 7.4), 150mM NaCl, 0.5% Igepal, 1 mM EDTA,
1mM DTT, 1mM PMSF, 0.2 mM Na3VO4, protease and phosphatase
inhibitors cocktail (Sigma/Aldrich). Nuclear proteins were released
with DNase I (20 U) in 20mM Tris-HCl (pH 7.4) 2.5 mM MgCl2, 20mM
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
IAIi002RSTS1-34-A IAIi002 Male 13 Caucasian c.4435G > T p.(Gly1479*) RSTS1
IAIi003RSTS1-46-A IAIi003 Female 14 Caucasian c.4627C > T p.(Asp1543Tyr) RSTS1
IAIi004RSTS1-149-A IAIi004 Male 7 Caucasian c.3474G > A p.(Trp1158*) RSTS1
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Fig. 1. Characterization of IAIi002, IAIi004, IAIi003.
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Table 2
Characterization and validation.
Category Test Details and Results Data
Phenotype Morphology Phase contrast microscopy revealed normal stem cell-like morphology Fig. 1A
Marker expression Immunofluorescence Positive for expression of pluripotency markers: SSEA4, OCT3/4, TRA-1-60 Fig. 1A
Flow cytometry Determined cell surface expression of SSEA4 and TRA-1-60 Fig. 1B FACS profiles available
with Authors
Genotype Karyotype (G-banding) or
alternative
IAIi002: 46XY. Q-banding shows normal karyotype at a resolution of 10Mb
IAIi003: 46XX. Q-banding shows normal karyotype at a resolution of 10Mb
IAIi004:46XY. Q-banding shows normal karyotype at a resolution of 10Mb
Supplementary Fig. S1
Reprogramming factors n/a n/a
Blood group genotyping n/a n/a
HLA tissue typing n/a n/a
Sequencing* Confirmed CREBBP mutations in exons 27 (IAIi002-A), 28 (IAIi003-A) and 18
(IAIi004-A)
Fig. 1D
Western Blot IAIi002-A: 46% reduction of full length CBP
IAIi003-A: full length CBP amount comparable to control
IAIi004-A: 68% reduction full length CBP
Fig. 1E-F
Southern Blot* n/a n/a
WGS n/a n/a
Identity* STR analysis Substituted by CNV Analysis
Number of markers tested: 20 (IAIi002-A); 27 (IAIi003-A); 11 (IAIi004-A)
100% matched against donors' PBMCs CNVs
with author(s)
Microsatellite PCR n/a n/a
Microbiology* Mycoplasma spp. Negative Myc test with author(s)
Virus screen SeV genome detected by RT- PCR in iPSCs at first passages, no more detectable at
passage 6.
with author(s)
Differentiation 3 germ layer differentiation Directed differentiation. Determined the expression of markers for each of the three
germ layers: NESTIN and PAX6 ectoderm; αSMA, mesoderm; SOX17, endoderm
Fig. 1C
Table 3
Antibody details.
Antibody description Conjugate Application Dilution Company Catalog # RRID
Rabbit anti-OCT3/4 IF Pluripotency Markers 1:200 Santa Cruz Biotechnology sc-9081 AB_2167703
Mouse anti-TRA-1-60 IF Pluripotency Markers 1:100 Santa Cruz Biotechnology sc-21,705 AB_628385
Mouse anti-SSEA4 IF Pluripotency Markers 1:100 Thermo Fisher Scientific 14-8843-80 AB_657847
Mouse anti-SSEA4 FACS Pluripotency Markers 1:100 Abcam ab16287 AB_778073
Mouse anti-TRA-1-60 FACS Pluripotency Markers 1:100 Abcam ab16288 AB_778563
Mouse anti-NESTIN IF Differentiation markers 1:150 Abcam ab22035 AB_446723
Rabbit anti-PAX6 IF Differentiation Markers 1:300 BioLegend PRB-278P AB_291612
Rabbit anti-SOX17 IF Differentiation markers 1:200 Cell Signaling Inc. 81,778 AB_2650582
Mouse anti-αSMA IF Differentiation markers 1:200 Millipore CBL171 AB_2223166
Rabbit polyclonal anti- CBP (A-22) WB 1:300 Santa Cruz Biotechnology sc-369 AB_631006
Mouse monoclonal anti-ACTIN antibody WB 1:2000 Sigma A3853 AB_262137
anti-rabbit IgG Secondary Antibody HRP WB 1:2000 Millipore AP307P AB_92641
anti-mouse IgG Secondary Antibody HRP WB 1:2000 Millipore AP124P AB_90456
F(ab’)2-Goat anti- Rabbit IgG(H+ L) Secondary
Antibody
Alexa®Fluor 555 IF 1:300 Thermo Fisher Scientific A-21430 AB_2535851
Anti-Mouse IgG Secondary Antibody Alexa®Fluor 488 IF 1:500 Thermo Fisher Scientific A-11001 AB_2534069
Anti-Mouse IgG Secondary Antibody Alexa®Fluor 488 FACS/IF 1:400 (for SSEA4)
1:300 (for NESTIN)
Thermo Fisher Scientific A11059 AB_2534106
Anti-Rabbit IgG Secondary Antibody Alexa®Fluor 488 IF 1:200 (for SOX17) Thermo Fisher Scientific A11034 AB_2576217
Anti-Mouse IgM Secondary Antibody Alexa®Fluor 488 FACS 1:200 (for TRA-1-60) Thermo Fisher Scientific A21042 AB_2535711
Anti-Mouse IgG2a Cross-Adsorbed Secondary
Antibody
Alexa®Fluor 633 IF 1:200 (for αSMA) Thermo Fisher Scientific A-21136 AB_2535775
Goat anti-Rabbit IgG (H+ L) Highly Cross-
Adsorbed Secondary Antibody
Alexa®Fluor 594 IF 1:300 (for PAX6) Thermo Fisher Scientific A-11037 AB_2534095
Table 4
Oligo details.
Oligo name Target Description Sequence (5′-3′) Product Size
CREBBP_Ex27_Forward CREBBP_ Ex27 c.4435G > T
(IAIi002-A)
Genomic CTTAAAGGCAGGGCCGATT 301 bp
CREBBP_Ex27_Reverse CREBBP_ Ex27 c.4435G > T
(IAIi002-A)
Genomic TGCAAGAAAAAGGCACACAA 301 bp
CREBBP_Ex28_Forward CREBBP_ Ex28 c.4627G > T
(IAIi003-A)
Genomic CACACATGCATGGGACTCTG 327 bp
CREBBP_Ex28_Reverse CREBBP_ Ex28 c.4627G > T
(IAIi003-A)
Genomic GACACGTGGGCAATGGAG 327 bp
CREBBP_Ex18_Forward CREBBP_ Ex18 c.3474G > A
(IAIi004-A)
Genomic GCCAGATGAGACTGGCATTT 445 bp
CREBBP_Ex18_Reverse CREBBP_ Ex18 c.3474G > A
(IAIi004-A)
Genomic CAGGCATCAACTGTGTCACC 445 bp
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NaCl, and 1mM PMSF (20min at 4 °C) mixed with the soluble fraction
in SDS-loading buffer and boiled at 70 ͦC for 10min. Proteins (120 μg)
were separated on NuPAGE 4–12% Bis-Tris Gel (Invitrogen), trans-
ferred to nitrocellulose and blocked with 5% BSA in PBS-0.2% Tween
20 (PBS-T). The membrane was incubated (1 h, RT) with antibodies to
CBP N-terminus and actin, (30min, RT) in HRP-labeled secondary an-
tibodies (Table 3), then washed in PBS-T, and chemiluminescence sig-
nals revealed with a Westar R imager (Hi-Tech Cyanagen). ImageJ was
used for densitometry.
Mycoplasma test
We ruled out the presence of Mycoplasma by using EZ-PCR
Mycoplasma Test Kit (Biological Industries) according to the manu-
facturer's instructions. Positive Control was included in the kit.
Resource table
Unique stem cell line
identifier
IAIi002-A
IAIi003-A
IAIi004-A
Link to hPSCreg entry https://hpscreg.eu/cell-line/IAIi002-A
https://hpscreg.eu/cell-line/IAIi003-A
https://hpscreg.eu/cell-line/IAIi004-A
Alternative name(s) of st-
em cell line
IAIi002RSTS1-34-A
IAIi003RSTS1-46-A
IAIi004RSTS1-149-A
Institution Istituto Auxologico Italiano (IAI)-IRCCS, Milan, Italy
Contact information of d-
istributor
Lidia Larizza, l.larizza@auxologico.it
Type of cell line iPSC
Origin Species: Human
Age: 13; 14; 7
Gender: Male; Female; Male
Ethnicity: Caucasian
Cell Source Peripheral blood mononuclear cells (PBMCs)
Clonality Clonal
Multiline rationale Same disease non-isogenic cell lines
Reprogramming method Sendai virus kit
Associated disease Rubinstein-Taybi syndrome 1 (RSTS1)
Disease associated locus CREBBP, 16p13.3
Known mutations or mo-
dification
Spontaneous mutation
c.4435G > T, p.(Gly1479*)
c.4627G > T, p.(Asp1543Tyr)
c.3474G > A, p.(Trp1158*)
Method of modification n/a
Name of transgene and/
or resistance
n/a
Inducible/constitutive sy-
stem
n/a
STR analysis Substituted by CNV Analysis
Number of CNVs tested: 20 (IAIi002-A); 27 (IAIi003-A);
11 (IAIi004-A)
100% matched against donors' PBMC CNVs
Date archived/stock date IAIi002-A: March 2016
IAIi003-A: November 2016
IAIi004-A: January 2018
Cell line repository/bank n/a
Ethical approval IAI Ethical Committee (CE). CE code: 12_15_2015_02
Have these lines been p-
ublished before
Yes
If yes, Publication refer-
ence/s
Alari V. et al., Stem Cell Res 30, 130–140. https://doi.
org/10.1016/j.scr.2018.05.019
Description of the publi-
cation
#34: IAIi002-A
#46: IAIi003-A
#149: IAIi004-A
iPSC generation described: Yes
QC assays done: Immunofluorescence, RT-PCR,
Karyotype, a-CGH, DNA sequencing, transcript sequen-
cing.
Novelty of current publication: in-depth characterization
(FACS, Trilineage Assay, Myc Test, Western Blot ana-
lysis) of three iPSC lines from RSTS1 donors with
different mutations and cognitive phenotypes which
embrace and validate the disease model.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2019.101553.
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